×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Clinical: COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT0607296
clinical
1,017 words
KG: COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
Contents
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (19)
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.61
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.65
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.78
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
Adenosine-Astrocyte Metabolic Reset
Score: 0.73
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.73
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.68
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.65
Digital Twin-Guided Metabolic Reprogramming
Score: 0.55
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.54
Show 14 more
Related Analyses (8)
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 3 more
Related Experiments (22)
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.51
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Show 17 more
Knowledge Graph (2 edges)
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
references
BDNF
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
references
NLRP3
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)